Arrowstreet Capital
VIVS

Arrowstreet Capital’s VivoSim Labs VIVS Stock Holding History

Arrowstreet Capital’s Portfolio VIVS Stock Details VIVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-256
Closed -$233K – 2594
2016
Q3 		$233K Buy
+256
New +$251K ﹤0.01% 1395

Other funds holding VIVS

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Arrowstreet Capital's VIVS Position: Q4 2016 in Review

Arrowstreet Capital sold out of VivoSim Labs (VIVS) in Q4 2016, closing a stake of 256 shares — an estimated $233K sold.

Arrowstreet Capital first reported a position in VIVS in Q3 2016 and held it in 1 quarter. The position peaked at $233K in Q3 2016. 128 funds tracked by Wall St. Rank hold VIVS as of Q4 2016.

  • Arrowstreet Capital reported no remaining VivoSim Labs position as of Q4 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 256 VivoSim Labs shares in Q4 2016, an estimated $233K.
  • Arrowstreet Capital first reported a position in VivoSim Labs in Q3 2016 and held it in 1 quarter.
  • Arrowstreet Capital's VivoSim Labs position peaked at $233K in Q3 2016.
  • 128 funds tracked by Wall St. Rank held VivoSim Labs as of Q4 2016.

Based on Arrowstreet Capital's 13F filing for Q4 2016, filed 15 Feb 2017.